RxDoctor Payments Data

Mac Montilus, MD

Internal Medicine · Lumberton, NCNPI 1922044791

Payments from drug & device makers

$824in general payments, 2019–2025

Across 20 payments — averaging $41.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$311
  • AstraZeneca$258
  • GSK$72
  • Bayer$47
  • Pfizer$45
  • Esperion Therapeutics, Inc.$24
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$824 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,237
Medicare patients
102
Services billed
957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$80,219
EliquisApixaban56$54,650
TrulicityDulaglutide40$48,811
RybelsusSemaglutide38$44,545
JardianceEmpagliflozin51$41,891
LinzessLinaclotide22$27,973
MounjaroTirzepatide20$23,169
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,093
JanuviaSitagliptin Phosphate29$21,989
Tresiba Flextouch U-100Insulin Degludec32$21,494
XareltoRivaroxaban14$7,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,069
Atorvastatin Calcium330$4,637
Pulmicort FlexhalerBudesonide23$4,402
Advair HfaFluticasone Propion/Salmeterol11$4,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$311$124,764103 claims
PfizerEliquis$45$54,65056 claims
AbbVieLinzess$20$27,97322 claims
GSKTrelegy Ellipta$72$22,09332 claims
AstraZenecaPulmicort Flexhaler$258$4,40223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →